Vaxcyte Executive Sells Shares After Exercising Options Struck at $5.35
Jim Wassil, Chief Operating Officer of Vaxcyte (NASDAQ:PCVX), sold a total of 6,182 shares for approximately $378,000 in late August and early September 2026. The transaction included the exercise of stock options with an exercise price of $5.35 per share—well below the weighted average sale price of $61.12—and subsequent sales under a Rule 10b5-1 trading plan established on December 9, 2025. Wassil also surrendered 2,705 shares to cover tax obligations from restricted stock unit vesting. After the transactions, he retained ownership of approximately 153,609 directly held shares and holds an additional 66,648 derivative securities. Wassil's remaining stake represents a 0.11% interest in Vaxcyte. Vaxcyte is currently trading at around $60.81 per share as of September 1, slightly below the average price achieved during Wassil’s transactions. The company remains focused on developing its lead vaccine candidate, VAX-24, and has a market capitalization of approximately $9 billion.
Tickers: $PCVX
Topics: insider transactions SEC Form 4 filing stock options exercise Vaxcyte